메뉴 건너뛰기




Volumn 44, Issue 2, 2014, Pages 155-161

Effect of TNF-alpha inhibitor treatment on bone mineral density in patients with ankylosing spondylitis: A systematic review and meta-analysis

Author keywords

Ankylosing spondylitis; Anti tumor necrosis factor alpha; BMD; Bone mineral density; Osteoporosis; Spondyloarthropathy; TNF inhibitors

Indexed keywords

ADALIMUMAB; BISPHOSPHONIC ACID DERIVATIVE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; PLACEBO; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

EID: 84906223977     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2014.05.008     Document Type: Article
Times cited : (62)

References (47)
  • 1
    • 79957505703 scopus 로고    scopus 로고
    • Population based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis
    • Bremander A., Petersson I.F., Bergman S., Englund M. Population based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res 2011, 63:550-556.
    • (2011) Arthritis Care Res , vol.63 , pp. 550-556
    • Bremander, A.1    Petersson, I.F.2    Bergman, S.3    Englund, M.4
  • 2
    • 0034894002 scopus 로고    scopus 로고
    • Changes in bone density in patients with ankylosing spondylitis: a two-year follow-up study
    • Maillefert J.F., Aho L.S., El Maghraoui A., Dougados M., Roux C. Changes in bone density in patients with ankylosing spondylitis: a two-year follow-up study. Osteoporos Int 2001, 12:605-609.
    • (2001) Osteoporos Int , vol.12 , pp. 605-609
    • Maillefert, J.F.1    Aho, L.S.2    El Maghraoui, A.3    Dougados, M.4    Roux, C.5
  • 3
    • 78149468158 scopus 로고    scopus 로고
    • Osteoporosis in ankylosing spondylitis
    • Magrey M., Khan M.A. Osteoporosis in ankylosing spondylitis. Curr Rheumatol Rep 2010, 12:332-336.
    • (2010) Curr Rheumatol Rep , vol.12 , pp. 332-336
    • Magrey, M.1    Khan, M.A.2
  • 4
    • 79955463371 scopus 로고    scopus 로고
    • The relation between bone mineral density, bone turnover markers, and vitamin D status in ankylosing spondylitis patients with active disease: a cross-sectional analysis
    • Arends S., Spoorenberg A., Bruyn G.A., Houtman P.M., Leijsma M.K., Kallenberg C.G., et al. The relation between bone mineral density, bone turnover markers, and vitamin D status in ankylosing spondylitis patients with active disease: a cross-sectional analysis. Osteoporos Int 2011, 22:1431-1439.
    • (2011) Osteoporos Int , vol.22 , pp. 1431-1439
    • Arends, S.1    Spoorenberg, A.2    Bruyn, G.A.3    Houtman, P.M.4    Leijsma, M.K.5    Kallenberg, C.G.6
  • 6
    • 72249084918 scopus 로고    scopus 로고
    • Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case-control study
    • Vosse D., Landewé R., van der Heijde D., van der Linden S., van Staa T.P., Geusens P. Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case-control study. Ann Rheum Dis 2009, 68:1839-1842.
    • (2009) Ann Rheum Dis , vol.68 , pp. 1839-1842
    • Vosse, D.1    Landewé, R.2    van der Heijde, D.3    van der Linden, S.4    van Staa, T.P.5    Geusens, P.6
  • 7
    • 78149237500 scopus 로고    scopus 로고
    • Increased fracture risk in patients with rheumatic disorders and other inflammatory diseases-a case-control study with 53,108 patients with fracture
    • Weiss R.J., Wick M.C., Ackermann P.W., Montgomery S.M. Increased fracture risk in patients with rheumatic disorders and other inflammatory diseases-a case-control study with 53,108 patients with fracture. J Rheumatol 2010, 37:2247-2250.
    • (2010) J Rheumatol , vol.37 , pp. 2247-2250
    • Weiss, R.J.1    Wick, M.C.2    Ackermann, P.W.3    Montgomery, S.M.4
  • 8
    • 84867080533 scopus 로고    scopus 로고
    • Vertebral fractures in ankylosing spondylitis are associated with lower bone mineral density in both central and peripheral skeleton
    • Klingberg E., Geijer M., Göthlin J., Mellström D., Lorentzon M., Hilme E., et al. Vertebral fractures in ankylosing spondylitis are associated with lower bone mineral density in both central and peripheral skeleton. J Rheumatol 2012, 39:1987-1995.
    • (2012) J Rheumatol , vol.39 , pp. 1987-1995
    • Klingberg, E.1    Geijer, M.2    Göthlin, J.3    Mellström, D.4    Lorentzon, M.5    Hilme, E.6
  • 9
    • 0033954933 scopus 로고    scopus 로고
    • The prevalence of vertebral fractures in mild ankylosing spondylitis and their relationship to bone mineral density
    • Mitra D., Elvins D.M., Speden D.J., Collins A.J. The prevalence of vertebral fractures in mild ankylosing spondylitis and their relationship to bone mineral density. Rheumatology (Oxford) 2000, 39:85-89.
    • (2000) Rheumatology (Oxford) , vol.39 , pp. 85-89
    • Mitra, D.1    Elvins, D.M.2    Speden, D.J.3    Collins, A.J.4
  • 10
    • 79955568036 scopus 로고    scopus 로고
    • Prevalence of vertebral fractures by semi automated morphometry in patients with ankylosing spondylitis
    • Montala N., Juanola X., Collantes E., Muñoz-Gomariz E., Gonzalez C., Gratacos J., et al. Prevalence of vertebral fractures by semi automated morphometry in patients with ankylosing spondylitis. J Rheumatol 2011, 38:893-897.
    • (2011) J Rheumatol , vol.38 , pp. 893-897
    • Montala, N.1    Juanola, X.2    Collantes, E.3    Muñoz-Gomariz, E.4    Gonzalez, C.5    Gratacos, J.6
  • 11
    • 0025265924 scopus 로고
    • Prevalence of vertebral compression fractures due to osteoporosis in ankylosing spondylitis
    • Ralston S.H., Urquhart G.D., Brzeski M., Sturrock R.D. Prevalence of vertebral compression fractures due to osteoporosis in ankylosing spondylitis. Br Med J 1990, 300:563-565.
    • (1990) Br Med J , vol.300 , pp. 563-565
    • Ralston, S.H.1    Urquhart, G.D.2    Brzeski, M.3    Sturrock, R.D.4
  • 12
    • 84855885230 scopus 로고    scopus 로고
    • Osteoporotic fractures: a systematic review of U.S. healthcare costs and resource utilization
    • Budhia S., Mikyas Y., Tang M., Badamgarav E. Osteoporotic fractures: a systematic review of U.S. healthcare costs and resource utilization. Pharmacoeconomics 2012, 30:147-170.
    • (2012) Pharmacoeconomics , vol.30 , pp. 147-170
    • Budhia, S.1    Mikyas, Y.2    Tang, M.3    Badamgarav, E.4
  • 13
    • 84891034178 scopus 로고    scopus 로고
    • Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research
    • Shane E., Burr D., Abrahamsen B., Adler R.A., Brown T.D., Cheung A.M., et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2014, 29:1-23.
    • (2014) J Bone Miner Res , vol.29 , pp. 1-23
    • Shane, E.1    Burr, D.2    Abrahamsen, B.3    Adler, R.A.4    Brown, T.D.5    Cheung, A.M.6
  • 14
    • 65249152431 scopus 로고    scopus 로고
    • Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis
    • Ciccia F., Bombardieri M., Principato A., Giardina A., Tripodo C., Porcasi R., et al. Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. Arthritis Rheum 2009, 60:955-965.
    • (2009) Arthritis Rheum , vol.60 , pp. 955-965
    • Ciccia, F.1    Bombardieri, M.2    Principato, A.3    Giardina, A.4    Tripodo, C.5    Porcasi, R.6
  • 15
    • 0037461609 scopus 로고    scopus 로고
    • Inhibition of tumor necrosis factor alpha and ankylosing spondylitis
    • Asli B., Wechsler B., Lemaître C. Inhibition of tumor necrosis factor alpha and ankylosing spondylitis. N Engl J Med 2003, 348:359-361.
    • (2003) N Engl J Med , vol.348 , pp. 359-361
    • Asli, B.1    Wechsler, B.2    Lemaître, C.3
  • 16
    • 0037783485 scopus 로고    scopus 로고
    • Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis
    • Brandt J., Khariouzov A., Listing J., Haibel H., Sörensen H., Grassnickel L., et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003, 48:1667-1675.
    • (2003) Arthritis Rheum , vol.48 , pp. 1667-1675
    • Brandt, J.1    Khariouzov, A.2    Listing, J.3    Haibel, H.4    Sörensen, H.5    Grassnickel, L.6
  • 17
    • 42449163799 scopus 로고    scopus 로고
    • Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitis
    • Gengenbacher M., Sebald H.J., Villiger P.M., Hofstetter W., Seitz M. Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis 2008, 67:620-624.
    • (2008) Ann Rheum Dis , vol.67 , pp. 620-624
    • Gengenbacher, M.1    Sebald, H.J.2    Villiger, P.M.3    Hofstetter, W.4    Seitz, M.5
  • 18
    • 69449100622 scopus 로고    scopus 로고
    • Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
    • Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Br Med J 2009, 339:b2535.
    • (2009) Br Med J , vol.339 , pp. b2535
    • Moher, D.1    Liberati, A.2    Tetzlaff, J.3    Altman, D.G.4
  • 19
    • 58849156499 scopus 로고    scopus 로고
    • Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis
    • Visvanathan S., van der Heijde D., Deodhar A., Wagner C., Baker D.G., Han J., et al. Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis 2009, 68:175-182.
    • (2009) Ann Rheum Dis , vol.68 , pp. 175-182
    • Visvanathan, S.1    van der Heijde, D.2    Deodhar, A.3    Wagner, C.4    Baker, D.G.5    Han, J.6
  • 20
    • 79952242241 scopus 로고    scopus 로고
    • The change of bone mineral density according to treatment agents in patients with ankylosing spondylitis
    • Kang K.Y., Lee K.Y., Kwok S.K., Ju J.H., Park K.S., Hong Y.S., et al. The change of bone mineral density according to treatment agents in patients with ankylosing spondylitis. Joint Bone Spine 2011, 78:188-193.
    • (2011) Joint Bone Spine , vol.78 , pp. 188-193
    • Kang, K.Y.1    Lee, K.Y.2    Kwok, S.K.3    Ju, J.H.4    Park, K.S.5    Hong, Y.S.6
  • 21
    • 84861303162 scopus 로고    scopus 로고
    • The effect of three years of TNF alpha blocking therapy on markers of bone turnover and their predictive value for treatment discontinuation in patients with ankylosing spondylitis: a prospective longitudinal observational cohort study
    • Arends S., Spoorenberg A., Houtman P.M., Leijsma M.K., Bos R., Kallenberg C.G., et al. The effect of three years of TNF alpha blocking therapy on markers of bone turnover and their predictive value for treatment discontinuation in patients with ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther 2012, 14:R98.
    • (2012) Arthritis Res Ther , vol.14 , pp. R98
    • Arends, S.1    Spoorenberg, A.2    Houtman, P.M.3    Leijsma, M.K.4    Bos, R.5    Kallenberg, C.G.6
  • 22
    • 84867325736 scopus 로고    scopus 로고
    • Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy?
    • Saad C.G., Ribeiro A.C., Moraes J.C., Takayama L., Goncalves C.R., Rodrigues M.B., et al. Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy?. Arthritis Res Ther 2012, 14:R216.
    • (2012) Arthritis Res Ther , vol.14 , pp. R216
    • Saad, C.G.1    Ribeiro, A.C.2    Moraes, J.C.3    Takayama, L.4    Goncalves, C.R.5    Rodrigues, M.B.6
  • 23
    • 84875608186 scopus 로고    scopus 로고
    • The paradoxical effects of TNF inhibitors on bone mineral density and radiographic progression in patients with ankylosing spondylitis
    • Kang K.Y., Ju J.H., Park S.H., Kim H.Y. The paradoxical effects of TNF inhibitors on bone mineral density and radiographic progression in patients with ankylosing spondylitis. Rheumatology (Oxford) 2013, 52:718-726.
    • (2013) Rheumatology (Oxford) , vol.52 , pp. 718-726
    • Kang, K.Y.1    Ju, J.H.2    Park, S.H.3    Kim, H.Y.4
  • 24
    • 44349177615 scopus 로고    scopus 로고
    • Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment
    • Briot K., Gossec L., Kolta S., Dougados M., Roux C. Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment. J Rheumatol 2008, 35:855-861.
    • (2008) J Rheumatol , vol.35 , pp. 855-861
    • Briot, K.1    Gossec, L.2    Kolta, S.3    Dougados, M.4    Roux, C.5
  • 25
    • 84885143496 scopus 로고    scopus 로고
    • Increase in bone density in ankylosing spondylitis during antiTNF therapy: a 6-year follow-up study
    • Durnez A., Paternotte S., Fechtenbaum J., Landewé R.B.M., Dougados M., Roux C., et al. Increase in bone density in ankylosing spondylitis during antiTNF therapy: a 6-year follow-up study. J Rheumatol 2013, 40:1712-1718.
    • (2013) J Rheumatol , vol.40 , pp. 1712-1718
    • Durnez, A.1    Paternotte, S.2    Fechtenbaum, J.3    Landewé, R.B.M.4    Dougados, M.5    Roux, C.6
  • 26
    • 84876666980 scopus 로고    scopus 로고
    • Infliximab improves bone metabolism and bone mineral density in rheumatoid arthritis and ankylosing spondylitis: a prospective 2-year study
    • Dischereit G., Tarner I.H., Müller-Ladner U., Lange U. Infliximab improves bone metabolism and bone mineral density in rheumatoid arthritis and ankylosing spondylitis: a prospective 2-year study. Clin Rheumatol 2013, 32:377-381.
    • (2013) Clin Rheumatol , vol.32 , pp. 377-381
    • Dischereit, G.1    Tarner, I.H.2    Müller-Ladner, U.3    Lange, U.4
  • 27
    • 80855131442 scopus 로고    scopus 로고
    • Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications
    • El Maghraoui A. Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications. Eur J Intern Med 2011, 22:554-560.
    • (2011) Eur J Intern Med , vol.22 , pp. 554-560
    • El Maghraoui, A.1
  • 28
    • 79953306817 scopus 로고    scopus 로고
    • Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis
    • Confavreux C.B., Chapurlat R.D. Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis. Osteoporos Int 2011, 22(4):1023-1036.
    • (2011) Osteoporos Int , vol.22 , Issue.4 , pp. 1023-1036
    • Confavreux, C.B.1    Chapurlat, R.D.2
  • 29
    • 70349454163 scopus 로고    scopus 로고
    • Effect of tumor necrosis factor alpha inhibition on bone density and turnover markers in patients with rheumatoid arthritis and spondyloarthropathy
    • Barnabe C., Hanley D.A. Effect of tumor necrosis factor alpha inhibition on bone density and turnover markers in patients with rheumatoid arthritis and spondyloarthropathy. Semin Arthritis Rheum 2009, 39:116-122.
    • (2009) Semin Arthritis Rheum , vol.39 , pp. 116-122
    • Barnabe, C.1    Hanley, D.A.2
  • 31
    • 84873743101 scopus 로고    scopus 로고
    • Osteoporosis drug therapy strategies in the setting of disease-modifying agents for autoimmune disease
    • Ricciardi B.F., Paul J., Kim A., Russell L.A., Lane J.M. Osteoporosis drug therapy strategies in the setting of disease-modifying agents for autoimmune disease. Osteoporos Int 2013, 24:423-432.
    • (2013) Osteoporos Int , vol.24 , pp. 423-432
    • Ricciardi, B.F.1    Paul, J.2    Kim, A.3    Russell, L.A.4    Lane, J.M.5
  • 33
    • 65749097416 scopus 로고    scopus 로고
    • Effects of biologic antirheumatic treatments on bone metabolism in rheumatoid arthritis and ankylosing spondylitis
    • Głuszko P. Effects of biologic antirheumatic treatments on bone metabolism in rheumatoid arthritis and ankylosing spondylitis. Endokrynol Pol 2009, 60:115-121.
    • (2009) Endokrynol Pol , vol.60 , pp. 115-121
    • Głuszko, P.1
  • 34
    • 84866791414 scopus 로고    scopus 로고
    • Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis
    • Taylan A., et al. Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis. BMC Musculoskelet Disord 2012, 13:191.
    • (2012) BMC Musculoskelet Disord , vol.13 , pp. 191
    • Taylan, A.1
  • 35
    • 22244493235 scopus 로고    scopus 로고
    • Bone loss in ankylosing spondylitis: can we put the puzzle together?
    • Wendling D. Bone loss in ankylosing spondylitis: can we put the puzzle together?. J Rheumatol 2005, 32:1184-1185.
    • (2005) J Rheumatol , vol.32 , pp. 1184-1185
    • Wendling, D.1
  • 36
    • 0037379299 scopus 로고    scopus 로고
    • Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor alpha
    • Allali F., Breban M., Porcher R., Maillefert J.F., Dougados M., Roux C. Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor alpha. Ann Rheum Dis 2003, 62:347-349.
    • (2003) Ann Rheum Dis , vol.62 , pp. 347-349
    • Allali, F.1    Breban, M.2    Porcher, R.3    Maillefert, J.F.4    Dougados, M.5    Roux, C.6
  • 38
    • 1842865931 scopus 로고    scopus 로고
    • Infliximab in spondylarthropathy-influence on bone density
    • Demis E., Roux C., Breban M., Dougados M. Infliximab in spondylarthropathy-influence on bone density. Clin Exp Rheumatol 2002, 20:S185-S186.
    • (2002) Clin Exp Rheumatol , vol.20 , pp. S185-S186
    • Demis, E.1    Roux, C.2    Breban, M.3    Dougados, M.4
  • 39
    • 13644257725 scopus 로고    scopus 로고
    • The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis
    • 2011 [accessed June 2013].
    • Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. 〈〉; 2011 [accessed June 2013]. http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm.
    • Wells, G.1    Shea, B.2    O'Connell, D.3    Peterson, J.4    Welch, V.5    Losos, M.6
  • 42
    • 22244433242 scopus 로고    scopus 로고
    • Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor {alpha} treatment
    • Briot K., Garnero P., Le Henaff A., Dougados M., Roux C. Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor {alpha} treatment. Ann Rheum Dis 2005, 64:1137-1140.
    • (2005) Ann Rheum Dis , vol.64 , pp. 1137-1140
    • Briot, K.1    Garnero, P.2    Le Henaff, A.3    Dougados, M.4    Roux, C.5
  • 43
    • 24944533001 scopus 로고    scopus 로고
    • The relative contributions of lean tissue mass and fat mass to bone density in young women
    • Wang M.C., Bachrach L.K., Van Loan M., Hudes M., Flegal K.M., Crawford P.B. The relative contributions of lean tissue mass and fat mass to bone density in young women. Bone 2005, 37:474-481.
    • (2005) Bone , vol.37 , pp. 474-481
    • Wang, M.C.1    Bachrach, L.K.2    Van Loan, M.3    Hudes, M.4    Flegal, K.M.5    Crawford, P.B.6
  • 44
    • 34447302822 scopus 로고    scopus 로고
    • Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50mg once-weekly and 25mg twice-weekly
    • Braun J., McHugh N., Singh A., Wajdula J.S., Sato R. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50mg once-weekly and 25mg twice-weekly. Rheumatology (Oxford) 2007, 46:999-1004.
    • (2007) Rheumatology (Oxford) , vol.46 , pp. 999-1004
    • Braun, J.1    McHugh, N.2    Singh, A.3    Wajdula, J.S.4    Sato, R.5
  • 45
    • 84867027990 scopus 로고    scopus 로고
    • Mucosal healing in inflammatory bowel diseases: a systematic review
    • Neurath M.F., Travis S.P. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 2012, 61:1619-1635.
    • (2012) Gut , vol.61 , pp. 1619-1635
    • Neurath, M.F.1    Travis, S.P.2
  • 46
    • 79956133759 scopus 로고    scopus 로고
    • Review article: the effects of antitumor necrosis factor-α on bone metabolism in inflammatory bowel disease
    • Veerappan S.G., O'Morain C.A., Daly J.S., Ryan B.M. Review article: the effects of antitumor necrosis factor-α on bone metabolism in inflammatory bowel disease. Aliment Pharmacol Ther 2011, 33:1261-1267.
    • (2011) Aliment Pharmacol Ther , vol.33 , pp. 1261-1267
    • Veerappan, S.G.1    O'Morain, C.A.2    Daly, J.S.3    Ryan, B.M.4
  • 47
    • 84885126123 scopus 로고    scopus 로고
    • The Impact of TNF-inhibitors on radiographic progression in ankylosing spondylitis
    • Haroon N., Inman R.D., Learch T.J., Weisman M.H., Lee M., Rahbar M.H., et al. The Impact of TNF-inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 2013, 65:2645-2654.
    • (2013) Arthritis Rheum , vol.65 , pp. 2645-2654
    • Haroon, N.1    Inman, R.D.2    Learch, T.J.3    Weisman, M.H.4    Lee, M.5    Rahbar, M.H.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.